BioSpace News Archive

Sophisticated liquid biopsy test could reduce the need for radiological studies such as PET/CT scans during post-radiation therapy surveillance

Expanding the Availailability & Support of Instadose® Personal Dosimetry Monitoring Solutions in Europe

Through a new $21 Million, Four-Year Investment, Amgen Scholars Program to Reach Additional 1,500 Undergraduates

MEI Pharma, Inc. (NASDAQ: MEIP), a late-stage pharmaceutical company focused on advancing new therapies for cancer, today announced that it will present data from three accepted abstracts related to MEI Pharma’s clinical stage drug development programs at the 2018 ASH Annual Meeting to be held December 1-4, 2018 in San Diego.

According to data compiled by Verified Market Intelligence, the global marijuana market was valued at USD 42.2 Billion in 2017 and is projected to reach USD 466.81 Billion

Company presents first clinically viable therapy to address a cancer with no effective targeted treatment

Xencor (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing monoclonal antibodies for the treatment of autoimmune disease, asthma and allergic diseases, and cancer, today announced that initial data from its ongoing Phase 1 dose-escalation study of XmAb®14045, a CD123 x CD3 bispecific antibody, in patients with relapsed/refractory acute myeloid leukemia (AML) will be presented

Both awards were presented on October 25, during the company’s 2018 International Seminar in Houston, Texas.

Risk stratification tool for Outpatient Total Joint Arthroplasty demonstrates improved predictive value for discharge to home, same day or next day

Oncopeptides AB (Nasdaq Stockholm: ONCO) announced today that the abstracts for the 60th American Society of Hematology (ASH) meeting (December 1st-4th, San Diego, California) have been released and include two melflufen presentations – one oral presentation (HORIZON) and one poster (ANCHOR)